636 related articles for article (PubMed ID: 14567964)
1. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.
Raper SE; Chirmule N; Lee FS; Wivel NA; Bagg A; Gao GP; Wilson JM; Batshaw ML
Mol Genet Metab; 2003; 80(1-2):148-58. PubMed ID: 14567964
[TBL] [Abstract][Full Text] [Related]
2. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.
Raper SE; Yudkoff M; Chirmule N; Gao GP; Nunes F; Haskal ZJ; Furth EE; Propert KJ; Robinson MB; Magosin S; Simoes H; Speicher L; Hughes J; Tazelaar J; Wivel NA; Wilson JM; Batshaw ML
Hum Gene Ther; 2002 Jan; 13(1):163-75. PubMed ID: 11779420
[TBL] [Abstract][Full Text] [Related]
4. Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.
Raper SE; Wilson JM; Yudkoff M; Robinson MB; Ye X; Batshaw ML
J Inherit Metab Dis; 1998; 21 Suppl 1():119-37. PubMed ID: 9686350
[TBL] [Abstract][Full Text] [Related]
5. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.
Kiwaki K; Kanegae Y; Saito I; Komaki S; Nakamura K; Miyazaki JI; Endo F; Matsuda I
Hum Gene Ther; 1996 May; 7(7):821-30. PubMed ID: 8860834
[TBL] [Abstract][Full Text] [Related]
6. Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus.
Mian A; McCormack WM; Mane V; Kleppe S; Ng P; Finegold M; O'Brien WE; Rodgers JR; Beaudet AL; Lee B
Mol Ther; 2004 Sep; 10(3):492-9. PubMed ID: 15336649
[TBL] [Abstract][Full Text] [Related]
7. Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes.
Morsy MA; Alford EL; Bett A; Graham FL; Caskey CT
J Clin Invest; 1993 Sep; 92(3):1580-6. PubMed ID: 8376608
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for ornithine transcarbamylase deficiency.
Kiwaki K; Matsuda I
Acta Paediatr Jpn; 1996 Apr; 38(2):189-92. PubMed ID: 8677801
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors.
Brunetti-Pierri N; Clarke C; Mane V; Palmer DJ; Lanpher B; Sun Q; O'Brien W; Lee B
J Gene Med; 2008 Aug; 10(8):890-6. PubMed ID: 18563850
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency.
Wilson JM; Shchelochkov OA; Gallagher RC; Batshaw ML
Mol Genet Metab; 2012 Feb; 105(2):263-5. PubMed ID: 22129577
[TBL] [Abstract][Full Text] [Related]
11. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors.
Mizuguchi H; Kay MA
Hum Gene Ther; 1999 Aug; 10(12):2013-7. PubMed ID: 10466635
[TBL] [Abstract][Full Text] [Related]
12. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.
Moscioni D; Morizono H; McCarter RJ; Stern A; Cabrera-Luque J; Hoang A; Sanmiguel J; Wu D; Bell P; Gao GP; Raper SE; Wilson JM; Batshaw ML
Mol Ther; 2006 Jul; 14(1):25-33. PubMed ID: 16677864
[TBL] [Abstract][Full Text] [Related]
13. Vector sequences are not detected in tumor tissue from research subjects with ornithine transcarbamylase deficiency who previously received adenovirus gene transfer.
Zhong L; Li S; Li M; Xie J; Zhang Y; Lee B; Batshaw ML; Wilson JM; Gao G
Hum Gene Ther; 2013 Sep; 24(9):814-9. PubMed ID: 24010702
[TBL] [Abstract][Full Text] [Related]
14. Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD).
Batshaw ML; Wilson JM; Raper S; Yudkoff M; Robinson MB
Hum Gene Ther; 1999 Sep; 10(14):2419-37. PubMed ID: 10515461
[No Abstract] [Full Text] [Related]
15. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse.
Ye X; Robinson MB; Pabin C; Batshaw ML; Wilson JM
Gene Ther; 2000 Oct; 7(20):1761-7. PubMed ID: 11083498
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.
Wang L; Morizono H; Lin J; Bell P; Jones D; McMenamin D; Yu H; Batshaw ML; Wilson JM
Mol Genet Metab; 2012 Feb; 105(2):203-11. PubMed ID: 22133298
[TBL] [Abstract][Full Text] [Related]
17. AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.
Wang L; Bell P; Morizono H; He Z; Pumbo E; Yu H; White J; Batshaw ML; Wilson JM
Mol Genet Metab; 2017 Apr; 120(4):299-305. PubMed ID: 28283349
[TBL] [Abstract][Full Text] [Related]
18. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors.
Ye X; Robinson MB; Batshaw ML; Furth EE; Smith I; Wilson JM
J Biol Chem; 1996 Feb; 271(7):3639-46. PubMed ID: 8631974
[TBL] [Abstract][Full Text] [Related]
19. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
20. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
